DDInter927 DDInter125
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent. Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with
Developed by Schering-Plough after its merger with Organon International, asenapine is a sublingually administered, atypical antipsychotic for treatment of schizophrenia and acute mania associated with bipolar disorder. Asenapine also belongs to the dibenzo-oxepino pyrrole class. It is also for severe post-traumatic stress disorder nightmares in soldiers as an off-label use. FDA approved on August 13, 2009.
Asenapine {u} (Compound) resembles {v} (Compound) Loxapine
Asenapine {u} (Compound) binds {v} (Gene) HRH2
Asenapine {u} (Compound) downregulates {v} (Gene) IGFBP2
Asenapine {u} (Compound) causes {v} (Side Effect) Parkinsonism
Asenapine (Compound) resembles Loxapine (Compound)
Asenapine (Compound) binds HRH2 (Gene)
Asenapine (Compound) downregulates IGFBP2 (Gene)
Asenapine (Compound) causes Parkinsonism (Side Effect)